Please login to the form below

ViraTherapeutics

This page shows the latest ViraTherapeutics news and features for those working in and with pharma, biotech and healthcare.

Boehringer links up with Trutino for cancer R&D

That includes the takeover of oncolytic virus specialist ViraTherapeutics at the end of 2018, which is focused on the latter’s lead candidate VSV-GP, a cancer therapy that works by

Latest news

Transgene slumps as viral cancer therapy fails phase 3 trial

Boehringer Ingelheim made a big play in the category when it bought ViraTherapeutics for $236m last September, as did Merck with its $394m purchase of Viralytics, while Abbvie and Johnson &Johnson
Boehringer taps Korea’s Bridge for Ofev follow-up

Last year, Boehringer also acquired the oncolytic virus specialist ViraTherapeutics for 210m and licensed a checkpoint inhibitor from OSE Immunotherapeutics in a deal valued at up to 1bn.
Boehringer bolts on another immuno-oncology company

Acquires ViraTherapeutics in a 210m takeover deal. Boehringer Ingelheim’s shopping spree in immuno-oncology has continued with a 210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working ... The privately-held German
Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

by ViraTherapeutics in 2016.
Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Boehringer Ingelheim has boosted its position in immuno-oncology by licensing an oncolytic virus therapy developed by Austrian biotech ViraTherapeutics. ... The deal also gives Boehringer an option to acquire ViraTherapeutics outright once phase I

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Deal Watch October 2018

AstraZeneca. Anti-NKG2A antibody (monalizumab), IPH5201 (antibody targeting CD38) and Lumoxiti. #. for hairy cell leukaemia. Development &. commercialisation. collaboration. $307m. ViraTherapeutics/. Boehringer Ingelheim.
Deal Watch September 2016

With a headline value of $235m Boehringer Ingelheim entered into a collaboration with ViraTherapeutics to develop an oncolytic virus therapy platform. ... Boehringer also secured the option to acquire ViraTherapeutics after development of VSV-GP. .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa: Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment: International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?: Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...